Lumos Pharma Inc. (LUMO)
4.34
0.00 (0.00%)
At close: Dec 11, 2024, 9:00 PM
0.00% (1D)
| Bid | n/a |
| Market Cap | 37.54M |
| Revenue (ttm) | 2.21M |
| Net Income (ttm) | -34.92M |
| EPS (ttm) | -4.28 |
| PE Ratio (ttm) | -1.014018691588785 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | n/a |
| Volume | 390,873 |
| Avg. Volume (20D) | 102,979 |
| Open | 4.33 |
| Previous Close | 4.34 |
| Day's Range | 4.33 - 4.34 |
| 52-Week Range | 1.37 - 4.58 |
| Beta | 0.33 |
About LUMO
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas....
Industry Biotechnology
Sector Healthcare
IPO Date Nov 11, 2011
Employees 30
Stock Exchange NASDAQ
Ticker Symbol LUMO
Website https://www.lumos-pharma.com
Analyst Forecast
According to 4 analyst ratings, the average rating for LUMO stock is "Hold." The 12-month stock price forecast is $8.62, which is an increase of 98.62% from the latest price.
Stock ForecastsNext Earnings Release
Lumos Pharma Inc. is scheduled to release its earnings on May 2, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
+10.38%
Lumos Pharma shares are trading higher. The compan...
Unlock content with
Pro Subscription
